Late entry to HIV care limits the impact of anti-retroviral therapy in the Netherlands

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  Smit, Colette ^a   Hallett, Timothy B ^b   Lange, Joep ^c   Garnett, Geoff ^b   de Wolf, Frank ^a,b  

^a STICHTING HIV MONITORING   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; EARLY INTERVENTION; FREQUENCY ANALYSIS; HEALTH CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MORTALITY; NETHERLANDS; PATIENT CARE; PATIENT MONITORING; PREDICTION; RISK FACTOR; RISK REDUCTION; SURVIVAL TIME; THERAPY DELAY; TREATMENT DURATION; CD4+ T LYMPHOCYTE; CELL COUNT; HEALTH CARE DELIVERY; MALE; METABOLISM; RISK; THEORETICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; COHORT STUDIES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MODELS, THEORETICAL; NETHERLANDS; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 44849110373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001949     Document Type: Article

References (20)

1. Gras L, van Sighem A, Smit C, Zaheri S, de Wolf F, on behalf of the Netherlands collaborative HIV treatment centres (2006) Monitoring of human immunodeficiency virus (HIV) type I in the Netherlands.
2. Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, et al. (2006) Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 3: e4.
3. Hallett TB, Gregson S, Dube S, Garnett GP (2008) The impact of monitoring HIV-infected patients prior to treatment in Resource-Poor Settings: Insights from Mathematical Modelling. PLoS Med 5: e53.
4. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
5. Egger M, May M, Cherie G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
6. Egger M (2007) Outcomes of Antiretroviral Treatment in Resource Limited and Industrialized Countries. in 14th Conference on Retrovirures and Opportunistic Infections (http://www.retroconference.org/2007/data/files/ webpage_for_CROI.htm) (Los Angeles, 2007).
7. Gras L, van Sighem A, Smit C, Zaheri S, de Wolf F, on behalf of the Netherlands collaborative HIV treatment centres (2006) Monitoring of human immunodeficiency virus (HM type 1 in the Netherlands.
8. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
9. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
10. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, et al. (2004) Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. Aids 18: 2145-2151.
11. Gras L, van Sighem A, Smit C, Zaheri S, de Wolf F, on behalf of the Netherlands collaborative HIV treatment centres (2006) Monitoring of human immunodeficiency virus (HIV) type 1 in the Netherlands.
12. Adu-Sarkodie Y, Sangare A, d'Almeida OA, Kanmogne GD (1998) Distribution of CD4+ T-lymphocytes levels in patients with clinical symptoms of AIDS in three west African countries. J Clin Virol 11: 173-181.
13. van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, et al. (2003) Mortality and progression to AIDS after starting highly active antiretroviral therapy. Aids 17: 2227-2236.
14. DeGruttola V, Lange eal N (1991) (2008) Modeling the progression of HIV infection. 86(415): 569-577.
15. Lepri AC, Sabin CA, Pezzotti P, England PD, Phillips AN, et al. (1997) Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study. J Infect Dis 175: 775-780.
16. McNeil AJ (1997) Bayes estimates for immunological progression rates in HIV disease. Stat Med 16: 2555-2572.
17. Fraser C, Ferguson NM, de Wolf F, Anderson RM (2001) The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. Proc Biol Sci 268: 2085-2095.
18. Margolick JB, Munoz A, Donnenberg AD, Park LP, Galai N, et al. (1995) Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med 1: 674-680.
19. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, et al. (1990) Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 3: 144-151.
20. Raboud JM, Haley L, Montaner JS, Murphy C, Januszewska M, et al. (1995) Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 10 Suppl 2: S67-S73.